Adverum Biotechnologies Inc (NASDAQ:ADVM) shares, rose in value, with the stock price down by -1.68% to the previous day’s close as strong demand from buyers drove the stock to $2.93.
Actively observing the price movement in the last trading, the stock closed the session at $2.98, falling within a range of $2.745 and $3.01. The value of beta (5-year monthly) was 1.091. Referring to stock’s 52-week performance, its high was $11.87, and the low was $2.89. On the whole, ADVM has fluctuated by -45.84% over the past month.
With the market capitalization of Adverum Biotechnologies Inc currently standing at about $61.21 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-14.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ADVM’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ADVM currently trading nearly -26.97% and -31.22% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 31.80, while the 7-day volatility ratio is showing 12.27% which for the 30-day chart, stands at 12.41%. Furthermore, Adverum Biotechnologies Inc (ADVM)’s beta value is 1.11, and its average true range (ATR) is 0.45.
A comparison of Adverum Biotechnologies Inc (ADVM) with its peers suggests the former has fared considerably weaker in the market. ADVM showed an intraday change of -1.68% in last session, and over the past year, it shrunk by -74.76%%.
Data on historical trading for Adverum Biotechnologies Inc (NASDAQ:ADVM) indicates that the trading volumes over the past 10 days have averaged 0.19 and over the past 3 months, they’ve averaged 170.31K. According to company’s latest data on outstanding shares, there are 20.85 million shares outstanding.
Nearly 41.50% of Adverum Biotechnologies Inc’s shares belong to company insiders and institutional investors own 59.17% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.49 million shares as on 2025-03-31, resulting in a short ratio of 9.77. According to the data, the short interest in Adverum Biotechnologies Inc (ADVM) stood at 720.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 1.49 million. The stock has fallen by -37.26% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ADVM stock heading into the next quarter.
